Inovio Pharmaceuticals Inc

Market Summary

USD0.380.00

Market Closed

0.00%

INO Stock Price

View Fullscreen

INO RSI Chart

INO Valuation

Market Cap

100.5M

Price/Earnings (Trailing)

-0.61

Price/Sales (Trailing)

15.6

EV/EBITDA

-0.51

Price/Free Cashflow

-0.74

INO Price/Sales (Trailing)

INO Profitability

EBT Margin

-1233.55%

Return on Equity

-99.44%

Return on Assets

-72.28%

Free Cashflow Yield

-134.31%

INO Fundamentals

INO Revenue

Revenue (TTM)

6.4M

Revenue Y/Y

-78.82%

Revenue Q/Q

-10.58%

INO Earnings

Earnings (TTM)

-164.5M

Earnings Y/Y

10.28%

Earnings Q/Q

4.6%

Price Action

52 Week Range

0.351.99

(Low)(High)

Last 7 days

-2.6%

Last 90 days

-15.9%

Trailing 12 Months

-79.2%

How does INO drawdown profile look like?

INO Financial Health

Current Ratio

3.91

INO Investor Care

Shares Dilution (1Y)

12.36%

Diluted EPS (TTM)

-0.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	12.3M	13.7M	6.4M	0
2022	2.7M	2.7M	11.5M	10.8M
2021	8.3M	8.2M	7.6M	2.8M
2020	2.6M	3.5M	3.6M	8.9M
2019	31.8M	7.5M	6.3M	4.1M
2018	39.3M	36.4M	33.4M	30.5M
2017	37.6M	51.8M	41.9M	42.2M
2016	43.5M	44.4M	32.8M	35.4M
2015	13.3M	14.8M	37.1M	40.6M
2014	14.4M	17.4M	9.7M	10.5M
2013	3.9M	4.2M	12.9M	13.5M
2012	8.4M	6.4M	4.6M	4.1M
2011	7.9M	9.2M	10.5M	9.8M
2010	8.4M	7.6M	6.9M	6.1M
2009	0	0	0	9.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for INO

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 30, 2023	sumner michael john	acquired	-	-	35,000	chief medical officer
Jun 05, 2023	zoth lota s.	sold	-3,192	0.56	-5,700	-
May 16, 2023	benito simon x	acquired	-	-	19,000	-
May 16, 2023	yarno wendy l	acquired	-	-	19,000	-
May 16, 2023	zoth lota s.	acquired	-	-	19,000	-
May 16, 2023	miller ann calby	acquired	-	-	19,000	-
May 16, 2023	shepard jay	acquired	-	-	19,000	-
May 16, 2023	weiner david b.	acquired	-	-	19,000	-
May 16, 2023	dansey roger d	acquired	-	-	19,000	-
May 13, 2023	dansey roger d	acquired	-	-	12,000	-

Which funds bought or sold INO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Dec 06, 2023	CITIGROUP INC	reduced	-29.27	-833	1,338	-%
Nov 17, 2023	JACOBS LEVY EQUITY MANAGEMENT, INC	reduced	-46.45	-511,438	447,340	-%
Nov 16, 2023	Creative Planning	reduced	-19.9	-2,422	5,596	-%
Nov 16, 2023	Financial Gravity Asset Management, Inc.	added	-	-10.00	7.00	-%
Nov 15, 2023	GSA CAPITAL PARTNERS LLP	new	-	116,000	116,000	0.01%
Nov 15, 2023	GTS SECURITIES LLC	new	-	5,728	5,728	-%
Nov 15, 2023	Tudor Investment Corp Et Al	reduced	-59.16	-159,209	87,922	-%
Nov 15, 2023	Virtu Financial LLC	sold off	-100	-21,000	-	-%
Nov 15, 2023	MORGAN STANLEY	reduced	-19.23	-49,837	118,349	-%
Nov 15, 2023	OLD MISSION CAPITAL LLC	sold off	-100	-47,296	-	-%

Latest Funds Activity

Are funds buying INO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INO

No. of Funds

Schedule 13G FIlings of Inovio Pharmaceuticals Inc

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jul 10, 2023	state street corp	0.33%	877,447	SC 13G/A
Jul 07, 2023	blackrock inc.	2.3%	6,086,623	SC 13G/A
Feb 09, 2023	state street corp	12.61%	31,472,352	SC 13G/A
Feb 09, 2023	vanguard group inc	6.83%	17,042,500	SC 13G/A
Jan 24, 2023	blackrock inc.	9.3%	23,284,119	SC 13G/A
Apr 11, 2022	state street corp	10.49%	23,267,928	SC 13G/A
Feb 11, 2022	state street corp	6.32%	13,300,430	SC 13G/A
Feb 01, 2022	blackrock inc.	8.7%	18,244,914	SC 13G/A
Feb 11, 2021	wasatch advisors inc	-	0	SC 13G/A
Feb 11, 2021	nikko asset management americas, inc.	0%	0	SC 13G/A

Recent SEC filings of Inovio Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Nov 28, 2023	DEF 14A	DEF 14A
Nov 17, 2023	PRE 14A	PRE 14A
Nov 09, 2023	S-3	S-3
Nov 09, 2023	8-K	Current Report
Nov 09, 2023	10-Q	Quarterly Report
Nov 02, 2023	8-K	Current Report
Oct 10, 2023	8-K	Current Report

Peers (Alternatives to Inovio Pharmaceuticals Inc)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
HILS	30.9B	-	5.25%	401813.88%	-3.6K	218.4K	-	-102.45%
MRNA	30.5B	10.7B	8.54%	-55.34%	-8.79	2.86	-53.67%	-129.46%
ALNY	22.2B	1.7B	4.15%	-23.37%	-43.62	12.9	79.37%	56.87%
BMRN	17.9B	2.3B	11.05%	-8.44%	121.62	7.74	15.05%	75.21%
INCY	12.4B	3.6B	0.84%	-34.33%	29.1	3.43	8.35%	-51.49%
MID-CAP
APLS	7.6B	272.9M	35.37%	34.74%	-12.51	27.78	141.38%	4.43%
BBIO	5.9B	-	14.36%	263.35%	-10.02	48.33	54.84%	-12.96%
ACAD	3.6B	631.9M	-7.32%	48.57%	-24.01	5.65	23.54%	31.53%
AXSM	3.3B	223.4M	11.28%	-10.13%	-16.47	14.87	-	-26.24%
ARWR	2.6B	240.7M	-10.83%	-25.35%	-12.82	10.93	-1.03%	-16.59%
SMALL-CAP
CPRX	1.5B	348.4M	11.36%	-14.92%	24.59	4.38	81.69%	-7.29%
NVAX	656.6M	1.0B	-22.00%	-67.89%	-1.2	0.63	-43.15%	58.48%
INO	100.5M	6.4M	-	-79.23%	-0.61	15.6	-44.11%	50.48%
IBIO	39.5M	-	376.67%	112.17%	-0.61	-	-	-29.23%
CRBP	23.3M	-	25.24%	3980.68%	-0.49	-	-	-13.74%

Inovio Pharmaceuticals Inc News

Latest updates

Stocks Register • 05 Dec 2023 • 04:04 pm • 3 days ago

When Would Be The Best Time To Buy Inovio Pharmaceuticals Inc ...

MarketWatch • 01 Dec 2023 • 10:30 pm • 6 days ago

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains

Yahoo Finance • 10 Nov 2023 • 08:00 am • 28 days ago

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call ...

StockNews.com • 10 Nov 2023 • 08:00 am • 28 days ago

GMAB: 3 Biotech Stocks to Watch in November

Stocks Register • 07 Nov 2023 • 08:00 am • 31 days ago

Inovio Pharmaceuticals Inc (NASDAQ: INO)'s Stock Hinders -0.10 ...

Seeking Alpha • 06 Nov 2023 • 08:00 am • 32 days ago

Protalix BioTherapeutics GAAP EPS of -$0.04 beats by $0.03 ...

PR Newswire • 01 Nov 2023 • 07:00 am • 37 days ago

INOVIO Reports Inducement Grants Under Inducement Plan

MarketWatch • 23 Oct 2023 • 07:00 am • 46 days ago

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors

Nasdaq • 19 Oct 2023 • 07:00 am • 50 days ago

Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why

Dhaka Tribune • 11 Oct 2023 • 07:00 am • 58 days ago

Inovio Pharma (NASDAQ: INO) up 50% on FDA decision - no Phase III required

Seeking Alpha • 09 Sep 2023 • 07:00 am • 3 months ago

Inovio Pharmaceuticals: Tightening The Ship, Finding An Inflection ...

Nasdaq • 07 Sep 2023 • 07:00 am • 3 months ago

INOVIO Says FDA Grants Breakthrough Therapy Designation For ...

PR Newswire • 29 Aug 2023 • 07:00 am • 3 months ago

INOVIO to Present at the H.C. Wainwright 25th Annual Global ...

BioWorld Online • 10 Aug 2023 • 07:00 am • 4 months ago

Other news to note for Aug. 10, 2023

Yahoo Finance • 09 Aug 2023 • 07:00 am • 4 months ago

Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue ...

Financials for Inovio Pharmaceuticals Inc

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-10.6%	1,938,745	2,168,233	2,207,171	124,666	9,154,133	857,667	669,814	839,115	291,698	928,111	769,237	5,580,581	896,710	1,067,399	1,327,274	279,488	866,863	135,674	2,829,905	2,502,624	2,000,868
Operating Expenses	-3.6%	35,941,458	37,267,068	44,067,121	56,070,821	44,911,177	104,921,721	71,932,069	106,347,454	60,244,852	83,474,759	52,925,612	34,920,019	36,565,618	33,448,085	26,559,542	30,700,541	24,818,650	28,336,367	31,364,917	32,001,788	28,643,551
S&GA Expenses	-26.6%	9,925,055	13,523,098	13,890,610	13,950,944	11,824,047	48,456,836	15,953,458	14,048,635	13,156,183	12,666,341	13,881,194	8,617,458	10,110,506	11,071,510	7,448,354	8,696,586	5,681,441	5,850,101	6,975,029	5,636,141	6,791,693
R&D Expenses	-34.7%	15,503,032	23,743,970	30,176,511	42,119,877	33,087,130	56,464,885	55,978,611	92,298,819	47,088,669	70,808,418	39,044,418	26,302,561	26,455,112	22,376,575	19,111,188	22,003,955	19,137,209	22,486,266	24,389,888	26,365,647	21,851,858
EBITDA Margin	100.0%	-	-12.01	-19.17	-26.57	-28.21	-216	-191	-168	-26.53	-16.00	-22.40	-17.38	-47.16	-59.99	-12.46	-7.66	-	-	-	-	-
Interest Expenses	0%	313,488	313,488	313,488	313,488	313,488	313,488	313,488	480,313	476,374	466,726	513,034	1,068,008	1,984,046	2,846,641	2,803,755	2,668,837	2,428,671	2,194,783	656,248	-156,261	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-87,764	-	-106,771	-62,800	-	-
Earnings Before Taxes	4.5%	-33,929,864	-35,534,533	-40,649,317	-54,463,139	-37,783,896	-108,497,311	-76,908,506	-106,947,580	-60,169,041	-82,139,958	-53,967,744	-22,415,201	20,931,010	-128,270,709	-33,135,404	-38,235,146	-23,536,452	-29,685,847	-29,351,667	-32,962,205	-25,015,672
EBT Margin	100.0%	-	-12.34	-19.56	-27.06	-28.66	-219	-194	-170	-27.19	-16.83	-23.21	-18.36	-50.05	-63.03	-13.56	-8.14	-	-	-	-	-
Net Income	4.6%	-33,900,000	-35,534,533	-40,649,317	-54,463,139	-37,783,896	-108,497,311	-79,073,719	-106,947,580	-60,169,041	-82,139,958	-54,402,131	-24,338,380	19,171,336	-129,172,466	-33,135,404	-37,662,038	-23,090,693	-29,387,226	-29,219,262	-32,962,205	-25,015,672
Net Income Margin	100.0%	-	-12.34	-19.55	-27.26	-28.84	-221	-196	-171	-27.48	-17.33	-23.78	-18.76	-50.33	-62.69	-13.35	-8.04	-	-	-	-	-
Free Cashflow	100.0%	-	-32,338,571	-36,961,461	-36,505,141	-67,552,146	-51,245,185	-61,882,102	-38,534,821	-46,659,317	-78,667,141	-53,078,252	-52,178,566	-74,540,403	-27,187,069	-25,593,673	-13,851,789	-	-	-	-	-

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-17.1%	193	233	267	349	392	459	446	496	536	592	655	540	438	443	339	144	152	165	191	131	141
Current Assets	-14.0%	175	203	234	315	350	416	400	448	487	542	588	471	377	382	276	94.00	99.00	111	135	88.00	94.00
Cash Equivalents	-64.3%	19.00	53.00	28.00	46.00	22.00	41.00	59.00	71.00	68.00	59.00	84.00	251	179	215	158	22.00	16.00	20.00	21.00	24.00	19.00
Net PPE	-10.7%	6.00	6.00	7.00	8.00	16.00	16.00	17.00	17.00	18.00	18.00	11.00	11.00	11.00	11.00	12.00	13.00	14.00	14.00	15.00	16.00	16.00
Goodwill	-100.0%	-	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00
Liabilities	-13.7%	55.00	64.00	67.00	126	125	162	90.00	96.00	82.00	83.00	73.00	79.00	114	257	151	139	115	109	110	44.00	37.00
Current Liabilities	-15.8%	44.00	52.00	55.00	97.00	95.00	131	59.00	66.00	51.00	52.00	42.00	42.00	41.00	38.00	32.00	32.00	20.00	24.00	27.00	35.00	28.00
Shareholder's Equity	-18.4%	138	169	199	222	267	298	355	400	454	509	582	461	324	186	188	5.00	36.00	56.00	81.00	87.00	104
Retained Earnings	-2.2%	-1,597	-1,564	-1,500	-1,487	-1,433	-1,400	-1,300	-1,209	-1,102	-1,000	-960	-906	-881	-901	-772	-739	-702	-679	-649	-620	-587
Additional Paid-In Capital	0.2%	1,737	1,734	1,728	1,711	1,701	1,694	1,642	1,610	1,557	1,551	1,542	1,367	1,206	1,088	958	743	735	732	727	708	691
Shares Outstanding	-100.0%	-	264	258	253	249	235	219	217	210	210	202	187	165	156	125	101	99.00	98.00	97.00	93.00	92.00
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	4.00	2.00	2.00	3.00	3.00	0.00	0.00

Cashflow (Last 12 Months)
(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	9.9%	-29,110	-32,314	-36,664	-36,340	-67,465	-50,527	-61,882	-37,891	-46,490	-78,459	-52,867	-51,216	-74,158	-27,151	-25,452	-13,737	-27,733	-23,924	-32,454	-17,281	-24,670
Share Based Compensation	-28.7%	2,079	2,918	3,809	3,274	3,234	8,336	7,711	5,474	5,620	5,646	9,596	3,825	4,158	3,662	4,002	2,034	2,080	3,355	3,433	2,138	2,351
Cashflow From Investing	-110.2%	-5,493	53,907	19,000	54,001	44,557	-10,304	21,332	-6,493	55,958	50,306	-275,115	-3,716	39,115	-42,385	-51,808	10,435	8,270	21,588	-49,337	7,183	14,418
Cashflow From Financing	-75.8%	699	2,883	-424	6,668	3,812	42,939	28,422	47,595	-440	3,441	160,903	126,939	-1,695	126,523	213,513	9,645	15,581	1,294	78,877	14,394	14,565

INO Income Statement

2023-09-30

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Revenue from collaborative arrangements and other contracts	$ 388,446	$ 9,154,133	$ 729,359	$ 10,137,602
Operating expenses:
Research and development	15,503,032	33,087,130	69,423,513	145,530,626
General and administrative	9,925,055	11,824,047	37,338,763	76,234,341
Impairment of goodwill	10,513,371	0	10,513,371	0
Total operating expenses	35,941,458	44,911,177	117,275,647	221,764,967
Loss from operations	(35,553,012)	(35,757,044)	(116,546,288)	(211,627,365)
Other income (expense):
Interest income	1,938,745	1,365,759	6,314,149	2,893,240
Interest expense	(313,488)	(313,488)	(940,464)	(940,464)
Gain (loss) on investment in affiliated entity	214,374	(305,061)	987,758	(1,776,804)
Net unrealized gain (loss) on available-for-sale equity securities	(219,337)	(1,833,284)	3,921,819	(10,641,026)
Other income (expense), net	2,854	(940,778)	(3,850,688)	(1,097,294)
Net loss before share in net loss of Geneos	(33,929,864)	(37,783,896)	(110,113,714)	(223,189,713)
Share in net loss of Geneos	0	0	0	(2,165,213)
Net loss	$ (33,929,864)	$ (37,783,896)	$ (110,113,714)	$ (225,354,926)
Net loss per share
Basic (in dollars per share)	$ (0.13)	$ (0.15)	$ (0.42)	$ (0.96)
Diluted (in dollars per share)	$ (0.13)	$ (0.15)	$ (0.42)	$ (0.96)
Weighted average number of common shares outstanding
Basic (in shares)	268,622,753	249,351,023	263,842,074	234,634,724
Diluted (in shares)	268,622,753	249,351,023	263,842,074	234,634,724

INO Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 18,804,602	$ 46,329,359
Short-term investments	148,668,866	206,669,397
Prepaid expenses and other current assets	5,114,873	50,130,481
Prepaid expenses and other current assets from affiliated entities	34,923	375,227
Total current assets	174,767,197	315,242,680
Fixed assets, net	5,632,511	7,727,997
Investment in affiliated entity	2,994,900	2,007,142
Intangible assets, net	0	2,129,861
Goodwill	0	10,513,371
Operating lease right-of-use assets	9,097,275	10,228,207
Other assets	605,315	684,044
Total assets	193,097,198	348,533,302
Current liabilities:
Accrued clinical trial expenses	5,011,185	10,594,073
Operating lease liability	2,117,971	2,803,973
Grant funding liability	3,806,161	2,475,031
Grant funding liability from affiliated entity	21,918	87,673
Convertible senior notes	16,488,329	0
Total current liabilities	43,711,026	96,868,074
Convertible senior notes	0	16,614,840
Operating lease liability, net of current portion	11,194,413	12,655,586
Deferred tax liabilities	32,046	32,046
Total liabilities	54,937,485	126,170,546
Stockholders’ equity:
Preferred stock	0	0
Common stock	269,730	253,090
Additional paid-in capital	1,736,602,555	1,710,656,191
Accumulated deficit	(1,597,961,498)	(1,487,847,784)
Accumulated other comprehensive loss	(751,074)	(698,741)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity	138,159,713	222,362,756
Total liabilities and stockholders’ equity	193,097,198	348,533,302
Nonrelated Party
Current assets:
Accounts receivable	0	1,701,726
Current liabilities:
Accounts payable and accrued expenses	15,553,742	79,686,885
Related Party
Current assets:
Accounts receivable	2,143,933	10,036,490
Current liabilities:
Accounts payable and accrued expenses	$ 711,720	$ 1,220,439

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

CEO	Dr. Jacqueline E. Shea Ph.D.
WEBSITE	www.inovio.com
EMPLOYEES	135

Inovio Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Inovio Pharmaceuticals Inc? What does INO stand for in stocks?

INO is the stock ticker symbol of Inovio Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inovio Pharmaceuticals Inc (INO)?

As of Thu Dec 07 2023, market cap of Inovio Pharmaceuticals Inc is 100.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INO stock?

You can check INO's fair value in chart. The fair value of Inovio Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inovio Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inovio Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether INO is over valued or under valued. Whether Inovio Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Inovio Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INO.

What is Inovio Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 07 2023, INO's PE ratio (Price to Earnings) is -0.61 and Price to Sales (PS) ratio is 15.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Inovio Pharmaceuticals Inc's stock?

In the past 10 years, Inovio Pharmaceuticals Inc has provided -0.358 (multiply by 100 for percentage) rate of return.

Market Summary

INO Stock Price

INO RSI Chart

INO Valuation

INO Price/Sales (Trailing)

INO Profitability

INO Fundamentals

INO Revenue

INO Earnings

Price Action

52 Week Range

How does INO drawdown profile look like?

INO Financial Health

INO Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for INO

Which funds bought or sold INO recently?

Latest Funds Activity

Schedule 13G FIlings of Inovio Pharmaceuticals Inc

Recent SEC filings of Inovio Pharmaceuticals Inc

Peers (Alternatives to Inovio Pharmaceuticals Inc)

Inovio Pharmaceuticals Inc News

Financials for Inovio Pharmaceuticals Inc

Income Statement (Last 12 Months)

Balance Sheet.css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Cashflow (Last 12 Months)(In Thousands)

INO Income Statement

INO Balance Sheet

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Inovio Pharmaceuticals Inc? What does INO stand for in stocks?

What is the market capital of Inovio Pharmaceuticals Inc (INO)?

What is the fair value of INO stock?

Is Inovio Pharmaceuticals Inc a good stock to buy?

What is Inovio Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

What is 5 year return on Inovio Pharmaceuticals Inc's stock?

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Thousands)